533 related articles for article (PubMed ID: 28674296)
21. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.
Kitazawa T; Igawa T; Sampei Z; Muto A; Kojima T; Soeda T; Yoshihashi K; Okuyama-Nishida Y; Saito H; Tsunoda H; Suzuki T; Adachi H; Miyazaki T; Ishii S; Kamata-Sakurai M; Iida T; Harada A; Esaki K; Funaki M; Moriyama C; Tanaka E; Kikuchi Y; Wakabayashi T; Wada M; Goto M; Toyoda T; Ueyama A; Suzuki S; Haraya K; Tachibana T; Kawabe Y; Shima M; Yoshioka A; Hattori K
Nat Med; 2012 Oct; 18(10):1570-4. PubMed ID: 23023498
[TBL] [Abstract][Full Text] [Related]
22. Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins.
Surowka M; Schaefer W; Klein C
MAbs; 2021; 13(1):1967714. PubMed ID: 34491877
[TBL] [Abstract][Full Text] [Related]
23. [Advances in research of bispecific antibodies for antivirus therapy].
Zhai G; Lu L; Lu H; Chen D
Sheng Wu Gong Cheng Xue Bao; 2019 Jul; 35(7):1174-1183. PubMed ID: 31328474
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.
Amann M; Brischwein K; Lutterbuese P; Parr L; Petersen L; Lorenczewski G; Krinner E; Bruckmeier S; Lippold S; Kischel R; Lutterbuese R; Kufer P; Baeuerle PA; Schlereth B
Cancer Res; 2008 Jan; 68(1):143-51. PubMed ID: 18172306
[TBL] [Abstract][Full Text] [Related]
25. Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation.
Muto A; Yoshihashi K; Takeda M; Kitazawa T; Soeda T; Igawa T; Sakamoto Y; Haraya K; Kawabe Y; Shima M; Yoshioka A; Hattori K
J Thromb Haemost; 2014 Feb; 12(2):206-13. PubMed ID: 24738137
[TBL] [Abstract][Full Text] [Related]
26. Redirecting adenoviruses to tumour cells using therapeutic antibodies: Generation of a versatile human bispecific adaptor.
Vasiljevic S; Beale EV; Bonomelli C; Easthope IS; Pritchard LK; Seabright GE; Caputo AT; Scanlan CN; Dalziel M; Crispin M
Mol Immunol; 2015 Dec; 68(2 Pt A):234-43. PubMed ID: 26391350
[TBL] [Abstract][Full Text] [Related]
27. Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3.
Schlereth B; Kleindienst P; Fichtner I; Lorenczewski G; Brischwein K; Lippold S; da Silva A; Locher M; Kischel R; Lutterbüse R; Kufer P; Baeuerle PA
Cancer Immunol Immunother; 2006 Jul; 55(7):785-96. PubMed ID: 16187083
[TBL] [Abstract][Full Text] [Related]
28. Tumor-antigen-binding bispecific antibodies for cancer treatment.
Weidle UH; Kontermann RE; Brinkmann U
Semin Oncol; 2014 Oct; 41(5):653-60. PubMed ID: 25440609
[TBL] [Abstract][Full Text] [Related]
29. [Bispecific antibodies: what future?].
Pèlegrin A; Robert B
Med Sci (Paris); 2009 Dec; 25(12):1155-8. PubMed ID: 20035697
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy with bispecific antibodies.
Thielemans KM
Verh K Acad Geneeskd Belg; 1995; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
[TBL] [Abstract][Full Text] [Related]
31. Bispecific antibody based therapeutics: Strengths and challenges.
Thakur A; Huang M; Lum LG
Blood Rev; 2018 Jul; 32(4):339-347. PubMed ID: 29482895
[TBL] [Abstract][Full Text] [Related]
32. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.
Muto A; Yoshihashi K; Takeda M; Kitazawa T; Soeda T; Igawa T; Sampei Z; Kuramochi T; Sakamoto A; Haraya K; Adachi K; Kawabe Y; Nogami K; Shima M; Hattori K
Blood; 2014 Nov; 124(20):3165-71. PubMed ID: 25274508
[TBL] [Abstract][Full Text] [Related]
33. Monoclonal and bispecific antibodies as novel therapeutics.
Booy EP; Johar D; Maddika S; Pirzada H; Sahib MM; Gehrke I; Loewen S; Louis SF; Kadkhoda K; Mowat M; Los M
Arch Immunol Ther Exp (Warsz); 2006; 54(2):85-101. PubMed ID: 16648969
[TBL] [Abstract][Full Text] [Related]
34. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
35. Bispecific antibodies in cancer immunotherapy.
Chen S; Li J; Li Q; Wang Z
Hum Vaccin Immunother; 2016 Oct; 12(10):2491-2500. PubMed ID: 27249163
[TBL] [Abstract][Full Text] [Related]
36. Bispecific antibody mimicking factor VIII.
Nogami K
Thromb Res; 2016 May; 141 Suppl 2():S34-5. PubMed ID: 27207420
[TBL] [Abstract][Full Text] [Related]
37. Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody.
Wimberger P; Xiang W; Mayr D; Diebold J; Dreier T; Baeuerle PA; Kimmig R
Int J Cancer; 2003 Jun; 105(2):241-8. PubMed ID: 12673686
[TBL] [Abstract][Full Text] [Related]
38. The coming of age of engineered multivalent antibodies.
Nuñez-Prado N; Compte M; Harwood S; Álvarez-Méndez A; Lykkemark S; Sanz L; Álvarez-Vallina L
Drug Discov Today; 2015 May; 20(5):588-94. PubMed ID: 25757598
[TBL] [Abstract][Full Text] [Related]
39. Bispecific antibody derivatives based on full-length IgG formats.
Grote M; Haas AK; Klein C; Schaefer W; Brinkmann U
Methods Mol Biol; 2012; 901():247-63. PubMed ID: 22723106
[TBL] [Abstract][Full Text] [Related]
40. [New hemophilia treatment employing a bispecific antibody to factors IXa and X].
Shima M
Rinsho Ketsueki; 2015 Jun; 56(6):623-31. PubMed ID: 26256871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
